-
1.发明公开公开(公告)号：US20240352139A1
公开(公告)日：2024-10-24
申请号：US18036144
申请日：2021-11-11
发明人： Xin GAO , Niliang QIAN , Xiujie PAN , Guili XU , Yujie LIU , Hongjie LI , Cuima YANG , Qinzhi XU , Xiaoqian DOU , Yunhui LIU , Zhenjun YU , Guijun BAI
CPC分类号： C07K16/2878 , A61P35/00 , C07K16/2803 , C07K16/2809 , C07K16/2827 , C07K16/2863 , C07K16/2866 , C07K16/30 , C07K16/3007 , C07K16/3069 , C07K16/3084 , C07K16/3092 , C07K2317/21 , C07K2317/31
摘要： The present application provides a fusion protein, containing: an anti-CD137 antibody capable of specifically binding to a CD137 molecule or an antigen binding fragment thereof; an anti-CD3 antibody capable of specifically binding to a CD3 molecule or an antigen binding fragment thereof; and a first peptide linker and a second peptide linker. The present application also provides a nucleic acid encoding the fusion protein, an expression vector containing the nucleic acid, a host cell containing the nucleic acid or the expression vector, a method for preparing the fusion protein, a pharmaceutical composition containing the fusion protein, and a use of the fusion protein.
-
公开(公告)号：US12065502B2
公开(公告)日：2024-08-20
申请号：US16750646
申请日：2020-01-23
发明人： Jonas Fast , Anja Sarah Paulus
CPC分类号： C07K16/3007 , A61K47/183 , A61K47/22 , A61K47/26 , C07K16/28 , C07K16/2803 , C07K16/2809 , A61K9/08 , A61K9/19 , C07K2317/31 , C07K2317/55
摘要： This invention relates to a pharmaceutical formulation of a bispecific antibody which binds to carcinoembryonic antigen (CEA) and CD3, a process for the preparation and uses of the formulation.
-
公开(公告)号：US20240218030A1
公开(公告)日：2024-07-04
申请号：US18289179
申请日：2022-05-03
申请人： CELLEMEDY CO., LTD
发明人： Jee Won LEE , Bo Ram LEE
CPC分类号： C07K14/47 , C07K16/084 , C07K16/2803 , C07K16/2806 , C07K16/2809 , C07K16/2818 , C07K16/2821 , C07K16/2827 , C07K16/2851 , C07K16/2863 , C07K16/2866 , C07K16/2875 , C07K16/2878 , C07K16/30 , C07K16/3007 , C07K16/3069 , C07K16/3084 , C07K16/3092 , C07K16/32 , C07K16/40 , C07K2319/30
摘要： A ferritin protein is mutated to have a foreign peptide fused to the outer surface thereof so that a binding force to a human transferrin receptor is reduced. The peptide can exhibit activities of various foreign peptides. The foreign peptide is a pharmacologically active peptide, and the foreign peptide may include a ligand or a fragment thereof, a receptor or a fragment thereof, an antibody or a fragment thereof including an antigen binding region (CDR), which are capable of binding to an immune checkpoint molecule; or a disease antigen epitope.
-
公开(公告)号：US20240190989A1
公开(公告)日：2024-06-13
申请号：US18513223
申请日：2023-11-17
发明人： Liang QU , Tong ZHANG , Zhuo LI , Xin CHEN , Lin ZHU , Penghao WANG , Xiaosui Zhou , Yuanyuan XIE , Jie LI , Jian SUN , Jing SONG , Xuehui LI
CPC分类号： C07K16/3007 , A61P35/00 , C07K16/2878 , A61K2039/505 , C07K2317/31 , C07K2317/52 , C07K2317/565 , C07K2317/732 , C07K2317/734
摘要： Multispecific antibodies and antigen-binding fragments thereof that bind to human CEA and CD137, a pharmaceutical composition comprising said antibody, and use of the multispecific antibody or the composition for treating.
-
公开(公告)号：US11945876B2
公开(公告)日：2024-04-02
申请号：US17807109
申请日：2022-06-15
CPC分类号： C07K16/3007 , A61K35/17 , A61P35/00 , C07K14/70521 , C07K14/70578 , A61K38/00 , A61K2039/505 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2319/02 , C07K2319/33
摘要： Some embodiments provided herein are chimeric costimulatory antigen receptor (CoStAR), useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. In some embodiments, the CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. In some embodiments, CoStAR and/or fusion proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof are also provided.
-
公开(公告)号：US11945807B2
公开(公告)日：2024-04-02
申请号：US17661909
申请日：2022-05-03
发明人： Ermira Pazolli , Silvia Buonamici , Thiwanka Samarakoon , Sudeep Prajapati , Nathan Fishkin , James Palacino , Michael Seiler , Ping Zhu , Andrew Cook , Peter Smith , Xiang Liu , Shelby Ellery , Dominic Reynolds , Lihua Yu , Zhenhua Wu , Shouyong Peng , Nicholas Calandra , Megan Sheehan , Yonghong Xiao
IPC分类号： C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/60 , A61K47/68 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
CPC分类号： C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/0011 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/60 , A61K47/6845 , A61K47/6849 , A61K47/6851 , A61K47/6857 , A61K47/6869 , A61K47/6871 , A61K47/6889 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/2827 , C07K16/2896 , C07K16/3007 , C07K16/3092 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/5011 , G01N33/574 , A61K2039/505 , A61K2039/53 , A61K2039/545 , C07K2317/565 , C07K2317/76 , C12Q2600/106 , G01N2500/10
摘要： Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US20240083998A1
公开(公告)日：2024-03-14
申请号：US18270706
申请日：2022-01-03
申请人： CIY OF HOPE
发明人： Defu ZENG , Qingxiao SONG , Arthur D. RIGGS
CPC分类号： C07K16/248 , A61K35/15 , A61K35/17 , A61P1/00 , A61P37/06 , C07K16/3007 , C07K16/40 , A61K2039/505
摘要： Disclosed is a method of preventing or treating acute GVHD (aGVHD) such as gut aGVHD, steroid-resistant aGVHD, and steroid-resistant gut aGVHD in a subject receiving a hematopoietic cell transplantation (HCT) or autoimmune colitis by administering to the subject an effective amount of an anti-IL-22 antibody, an anti-IL-6 antibody, donor-type CX3CR1hi MNPs, donor-type NK cells, a ceacam-1 antagonist, an anti-Gr-1 antibody, or a combination thereof.
-
公开(公告)号：US20240082437A1
公开(公告)日：2024-03-14
申请号：US18271835
申请日：2022-01-10
CPC分类号： A61K51/1048 , A61P35/00 , C07K16/3007
摘要： The present invention relates to antibodies which bind to antigens on target cells and which target effector moieties to said cells, and to methods of using the same.
-
公开(公告)号：US11858973B2
公开(公告)日：2024-01-02
申请号：US17263122
申请日：2019-07-24
申请人： UNIVERSIDAD DE ZARAGOZA , FUNDACIÓN AGENCIA ARAGONESA PARA LA INVESTIGACIÓN Y EL DESARROLLO (ARAID) , FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA
发明人： Luis Alberto Anel Bernal , Raquel Ibañez Perez , Patricia Guerrero Ochoa , Luis Martinez Lostao , Blanca Conde Guerri , Ramón Hurtado Guerrero , Ana Laura Sanz Alcober , Rocio Navarro Ortiz
CPC分类号： C07K14/47 , A61P35/00 , C07K16/3007 , C12N15/815 , A61K38/00 , A61K2039/505 , C07K2317/622 , C07K2319/02 , C12R2001/84
摘要： The present invention relates to granulysin, method of obtaining same, and uses, specifically to the granulysin polypeptide for the use thereof as a medicinal product via the systemic route and to a chimeric molecule comprising a recombinant antibody targeting a tumor antigen and the granulysin polypeptide.
-
公开(公告)号：US20230365711A1
公开(公告)日：2023-11-16
申请号：US18180977
申请日：2023-03-09
申请人： Roche Glycart AG
发明人： Thomas U. Hofer , Ralf Hosse , Ekkehard Moessner , Pablo Umana
IPC分类号： C07K16/42 , C07K16/30 , A61K39/395 , A61K45/06 , A61N5/10
CPC分类号： C07K16/42 , C07K16/3007 , A61K39/39566 , A61K45/06 , A61N5/10 , A61K2039/505
摘要： The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
-
-
-
-
-
-
-
-
-
搜索结果
786 条记录 (耗时 0.033 秒)
